Tavapadon Shows Promise for Parkinson's Disease Treatment in Phase 3 Trials
Key Insights
Tavapadon, a selective D1/D5 dopamine receptor agonist, demonstrated significant motor function improvements in two Phase 3 trials for Parkinson's disease (search) patients.
The TEMPO-1 study showed clinically meaningful reductions in MDS-UPDRS scores for early-stage patients, while TEMPO-3 demonstrated increased "on" time for patients already receiving levodopa.
The drug exhibited a favorable safety profile with lower rates of impulse control disorders and hallucinations compared to traditional dopamine agonists targeting D2/D3 receptors.
Two Phase 3 clinical trials have demonstrated that tavapadon, a novel dopamine receptor agonist developed by AbbVie (search), significantly improves motor symptoms in patients with Parkinson's disease (search), offering a potential new treatment option with an improved safety profile compared to existing therapies.
Novel Mechanism Targets Different Dopamine Receptors
Tavapadon represents a fundamentally new approach to Parkinson's disease (search) treatment by selectively targeting D1 and D5 dopamine receptors, rather than the D2/D3 receptors targeted by traditional dopamine agonists. This mechanism is designed to improve motor control while avoiding adverse effects commonly associated with conventional dopaminergic therapies.
"While levodopa remains the most effective therapy for Parkinson's disease (search), many patients eventually develop motor fluctuations (search) and other motor complications that significantly affect quality of life," said Dr. Zoltan Mari, Director of the Parkinson's Disease & Movement Disorders Program at the Cleveland Clinic Lou Ruvo Center for Brain Health. "Tavapadon represents such a new direction by selectively targeting D1/D5 receptors, rather than the D2/D3 receptors that are implicated in many of the problematic side effects of older dopamine agonists."
TEMPO-1 Trial Results in Early Disease
The TEMPO-1 study, a Phase 3, double-blind, placebo-controlled trial, enrolled 529 participants with early Parkinson's disease (search) across 102 sites in 12 countries between December 2019 and June 2024. Participants were randomized to receive either tavapadon 5 mg, tavapadon 15 mg, or placebo for 27 weeks.
Both doses of tavapadon demonstrated statistically significant improvements in motor function. The change from baseline to week 26 in the Movement Disorder Society–Unified Parkinson's Disease (search) Rating Scale (MDS-UPDRS) parts II and III combined score showed substantial improvements: -11.5 points for the 5-mg dose (95% CI, -13.8 to -9.2; P < .001; d = 1.14) and -12.1 points for the 15-mg dose (95% CI, -14.4 to -9.8; P < .001; d = 1.20).
TEMPO-3 Trial Shows Benefits for Advanced Patients
The TEMPO-3 study evaluated tavapadon as an adjunctive therapy in 507 patients already receiving levodopa who experienced motor fluctuations (search). Participants had a mean of 6.7 years since diagnosis and experienced an average of 5.52 hours of daily "off" time at baseline.
Results showed that total daily good "on" time increased by 1.7 hours for the tavapadon group compared to 0.6 hours for placebo (difference = 1.1; 95% CI, 0.6-1.7). "Off" time decreased by 1.88 hours for the treatment group versus 0.93 hours for placebo (difference = -0.94; 95% CI, -1.48 to -0.41).
The treatment group also showed improvements in MDS-UPDRS part II scores (-1.4 points vs -0.1 point for placebo; difference = -1.2; 95% CI, -2.2 to -0.2) and part III scores (-7 points vs -4.6 points for placebo; difference = -2.4; 95% CI, -4.3 to -0.5).
Favorable Safety Profile
Across both trials, tavapadon demonstrated a favorable safety profile. In TEMPO-1, common adverse events included nausea (25.4%), headache (16.7%), and dizziness (12.7%). In TEMPO-3, 71.1% of the treatment group experienced one or more adverse events compared to 55.1% of the placebo group, with 93.2% classified as nonserious and mild to moderate.
Notably, tavapadon showed very low rates of impulse control disorders and hallucinations compared to traditional dopamine agonists. Somnolence rates were comparable to placebo at 5.2% versus 4.3%, which Dr. Mari called "unexpected" and "encouraging."
Clinical Implications and Future Directions
The effect sizes observed in both trials support tavapadon's therapeutic relevance for Parkinson's disease (search) treatment. Dr. Mari highlighted that the increase in good "on" time without dyskinesia (search) represents "one of the most important treatment goals for patients with advanced PD."
In the TEMPO-4 open-label extension study, nearly 90% of patients did not require levodopa dose adjustments, suggesting durability of benefit that exceeded initial expectations.
The FDA has not yet approved tavapadon, and researchers are calling for long-term safety and efficacy studies, particularly in underrepresented populations. Future research will focus on evaluating long-term outcomes, disease progression effects, and comparative effectiveness against existing treatments to optimize treatment strategies in routine clinical practice.